1. Home >
  2. Curia Acquires Whitehouse Laboratories

M&A Deal Summary

Curia Acquires Whitehouse Laboratories

On December 15, 2015, Curia acquired life science company Whitehouse Laboratories for 54M USD

Acquisition Highlights
  • This is Curia’s 5th transaction in the Life Science sector.
  • This is Curia’s 5th largest (disclosed) transaction.
  • This is Curia’s 4th transaction in the United States.
  • This is Curia’s 1st transaction in New Jersey.

M&A Deal Summary
Date 2015-12-15
Target Whitehouse Laboratories
Sector Life Science
Buyer(s) Curia
Deal Type Add-on Acquisition
Deal Value 54M USD

Target

Whitehouse Laboratories

Lebanon, New Jersey, United States
Whitehouse Laboratories is a comprehensive analytical testing laboratory that offers USP-NF, EP, FCC and JP Monograph testing.

Search 205,036 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Curia

Albany, New York, United States
Category Company
Founded 1991
Sector Life Science
Employees2,220
Revenue 402M USD (2015)
DESCRIPTION

Curia is a provider of global contract research and manufacturing services to the pharmaceutical and biotechnology industries. The company's services include drug discovery, such as medicinal chemistry, discovery biology, and in vitro ADME, development, such as pre-formulation, formulation and validation and manufacturing, such as CGMP API manufacturing. Curia was founded in 1991 and is based in Albany, New York.

DEAL STATS #
Overall 7 of 11
Sector (Life Science) 5 of 9
Type (Add-on Acquisition) 6 of 8
State (New Jersey) 1 of 2
Country (United States) 4 of 7
Year (2015) 3 of 3
Size (of disclosed) 5 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-07-16 Gadea Grupo Farmacéutico SL

Valladolid, Spain

Gadea Grupo Farmacéutico SL (Gadea Pharmaceutical Group) is a technically complex active pharmaceutical ingredients (APIs) and finished drug product.

Buy $174M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-05-05 Archimica

Lodi, Italy

Archimica offers small- to large-scale commercial manufacturing as well as analytical support for the global biopharmaceutical market. The company is specialized in custom synthesis and the manufacture of active pharmaceutical ingredients (“APIs”). Archimica was founded in 1946 and is based in Lodi, Italy.

Buy $358M
Mergr

Product

Company

Legal